SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $74.9 million in its fourth quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 54 cents.
The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share.
The immuno-oncology company posted revenue of $51,000 in the period.
For the year, the company reported that its loss widened to $257 million, or $1.89 per share. Revenue was reported as $38.5 million.
Allogene Therapeutics shares have dropped 39% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $9.17, a decline of 73% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News